Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine (131I) therapy for hyperthyroid Graves' disease.

The outcome of 131I therapy for 109 patients with Graves' disease was analysed according to pretreatment laboratory data including thyrotropin receptor antibody (TRAb) activities. Forty-five percent of patients became euthyroid, and 13% of patients became hypothyroid within one year after 131I therapy. Forty-two percent of patients remained hyperthyroid one year after 131I therapy. Pretreatment values for serum T4, T3, and the estimated weight of the thyroid were significantly higher in the hyperthyroid group. The mean for the TRAb index of the hyperthyroid group was significantly higher than that of the euthyroid group. Life table analysis revealed a significant effect of the TRAb index on the rate of hyperthyroidism after 3 months or later. These results appear to suggest that the TRAb index is one of the factors which influence the outcome of 131I therapy for Graves' disease.

[1]  L. Degroot,et al.  Comparison of RA 131I treatment protocols for Graves’ disease , 1990, Journal of endocrinological investigation.

[2]  R. Holle,et al.  Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. , 1989, Acta endocrinologica.

[3]  S. Nagataki,et al.  Radioiodine (131I) therapy of Graves' disease: use of the new high resolutional ultrasonic scanner for the determination of the accurate weight of the thyroid gland. , 1989, Endocrinologia japonica.

[4]  M. Jonckheer,et al.  TREATMENT OF HYPERTHYROIDISM WITH RADIOIODINE: ADJUNCTIVE THERAPY WITH ANTITHYROID DRUGS RECONSIDERED , 1988, The Lancet.

[5]  A. Goolden,et al.  LONG‐TERM RESULTS FROM GRADED LOW DOSE RADIOACTIVE IODINE THERAPY FOR THYROTOXICOSIS , 1986, Clinical endocrinology.

[6]  E. Kaplan,et al.  Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. , 1984, The New England journal of medicine.

[7]  B. Smith,et al.  A RECEPTOR ASSAY FOR THE MEASUREMENT OF TSH RECEPTOR ANTIBODIES IN UNEXTRACTED SERUM , 1984, Clinical endocrinology.

[8]  B. Smith,et al.  AN IMPROVED RADIORECEPTOR ASSAY FOR TSH RECEPTOR ANTIBODIES , 1982, Clinical endocrinology.

[9]  N. Farid,et al.  PREDICTION OF THERAPEUTIC RESPONSE TO RADIOACTIVE IODINE IN GRAVES’DISEASE USING TSH‐RECEPTOR ANTIBODIES AND HLA‐STATUS , 1982, Clinical endocrinology.

[10]  K. Yoshinaga,et al.  Long-term results of radioiodine (131I) therapy in 331 patients with Graves' disease. , 1980, The Tohoku journal of experimental medicine.

[11]  A. McGregor,et al.  Carbimazole and the autoimmune response in Graves' disease. , 1980, The New England journal of medicine.

[12]  F. Maloof,et al.  Low-Dosage 131I Therapy of Thyrotoxicosis (Diffuse Goiters) , 1974 .

[13]  B. Rapoport,et al.  Low-dose sodium iodide I 131 therapy in Graves disease. , 1973, JAMA.

[14]  T. Fraser,et al.  Effect of Pretreatment with Carbimazole in Patients with Thyrotoxicosis Subsequently Treated with Radioactive Iodine , 1969, British medical journal.

[15]  R. Smith,et al.  Clinical trial of different doses of 131-I in treatment of thyrotoxicosis. , 1967, British medical journal.

[16]  W. W. Buchanan,et al.  Effect of Pretreatment with Methylthiouracil on Results of 131I Therapy , 1960, British medical journal.

[17]  W. Mosher,et al.  Protection of mice against x-radiation by thiourea. , 1950, Science.